Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
RaQualia Pharma 9-Mos Loss Y493.00M Vs Loss Y568.00M
RaQualia Pharma Inc. (4579.TO) Japan Nine Months Ended September 30 GROUP 2026 2025 Revenue Y2.35 bln Y2.31 bln Operating Profit (Y238.00 mln) (Y344.00 mln) Pretax Profit (Y261.00 mln) (Y426.00 mln) Net Profit (Y493.00 mln) (Y568.00 mln) Per share…
Kubota Pharma 9-Mos Loss Y908.00M Vs Loss Y435.00M
Kubota Pharmaceutical Holdings Co. Ltd. (4596.TO) Japan Nine Months Ended September 30 GROUP 2026 2025 Revenue Y11.00 mln Y18.00 mln Operating Profit (Y911.00 mln) (Y654.00 mln) Pretax Profit (Y908.00 mln) (Y435.00 mln) Net Profit (Y908.00 mln)…
Royalty Pharma: Stronger Royalty Growth Supports Further Upside
Royalty Pharma's Q3 royalty receipts increased 9% to $883 million, led by strong growth in Tremfya, Voranigo, and Evrysdi. Vertex now accounts for approximately 25% of royalty receipts, indicating that newer medicines are gradually reducing the…
Acurx Pharma (ACXP) Q3 2026 Earnings Call Transcript
Chief Financial Officer - Robert G. Shawah President and CEO - David Luci Executive Chairman - Bob DeLuccia Senior Medical Advisor - Dr. Michael Silverman Cash Balance -- $9.7 million as of Sept. 30, 2026, compared to $7.6 million on Dec. 31, 2025.
Fennec Pharma (FENC) Q3 2026 Earnings Call Transcript
Chief Financial Officer - Robert C. Andrade Chief Executive Officer and board member - Jeffrey S. Hackman Net Product Sales -- $19.4 million, representing an increase of approximately 56% year over year. Non-GAAP Adjusted EBITDA -- $5.8 million…
Zealand Pharma seeks partners for rare-disease assets as obesity focus grows
By Jesus Calero and Vera Dvorakova Nov 12 (Reuters) – Danish biotech Zealand Pharma has resumed talks with potential partners for rare-disease drug glepaglutide as it focuses investment on its obesity pipeline, the company's…
Ascendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.05, FiscalAI…
Ascendis Pharma A/S Q3 Earnings Call Highlights
Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/ S NASDAQ: ASND reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently…
HC Wainwright Issues Positive Forecast for Spyglass Pharma (NASDAQ:SGP) Stock Price
Spyglass Pharma (NASDAQ:SGP - Get Free Report) had its price target hoisted by equities researchers at HC Wainwright from $37.00 to $43.00 in a report released on Thursday, Benzinga reports. The firm presently has a 'buy' rating on the stock. HC…
Avalyn Pharma (NASDAQ:AVLN) Stock: Insider Fmr Llc Sells 175,000 Shares
Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) insider Fmr Llc sold 175,000 shares of the firm's stock in a transaction on Monday, November 9th. The stock was sold at an average price of $29.07, for a total value of $5,087,250.00. Following the…
Avalyn Pharma (NASDAQ:AVLN) Insider Fmr Llc Sells 53,454 Shares of Company Stock
Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) insider Fmr Llc sold 53,454 shares of the company's stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $30.21, for a total value of $1,614,845.34.
The Illusion Of The Industry Standard: Cyber Resilience Across Sectors
Sivan Tehila is the CEO and Founder of Onyxia Cyber and Cybersecurity Masters Program Director at the YU Katz School of Science and Health. For years, “industry standard” has done a great deal of quiet work in cybersecurity.
BridgeBio Pharma (NASDAQ:BBIO) Stock Purchase Reported by Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in…
Royalty Pharma PLC $RPRX Stock Sold by New South Capital Management Inc.
New South Capital Management Inc. trimmed its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 39.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund…
Kennedy's Future: Will Democrats Try to Impeach Him, or Actually Work With Him?
Three days after last week's “blue wave” election, Health Secretary Robert F. Kennedy Jr. posted a warning on X to anyone suspecting his Make America Healthy Again movement had been weakened. “It's time to unleash the…
Receive a Daily briefing on Pharma Industry News
Get Started